On June 22, Kelun-Biotech (06990.HK) fell 3.7% in regular trading, trading at 390.0 HKD/share, with turnover of approximately 54.37 million HKD. The decline came amid broad weakness across the biotechnology sector.

Within the Biotechnology sector, major peers experienced significant selling pressure. Among individual stocks, Akeso down 6.68%, Remegen down 5.04%, 3SBio down 4.68%, Innovent Biologics down 3.94%, and BeiGene down 3.48%. The sector-wide pullback weighed broadly on biotech names regardless of individual fundamentals.

Notably, the stock had previously rallied on multiple positive catalysts, including the disclosure of Phase III lung cancer data for its core asset sac-TMT at the ASCO conference and receipt of 703 million RMB in settlement payments from Yilian Bio related to ADC pipeline licensing disputes. Xingye Securities initiated coverage with a Buy rating, projecting revenue of 3.587 billion, 4.355 billion, and 6.712 billion RMB for the next three years respectively. The current decline appears driven primarily by broader sector rotation rather than company-specific negative developments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)